Louis M. Weiner, MD, was named director of Georgetown Lombardi Comprehensive Cancer Center at Georgetown University in October 2007. He is responsible for the operation and development of the cancer center, including its educational, research and clinical missions. Dr. Weiner is associate vice president at Georgetown University Medical Center, chair of the oncology department at Georgetown’s School of Medicine, and clinical director of cancer services at MedStar Georgetown University Hospital.
In November 2017, Weiner was named director of the new MedStar Georgetown Cancer Institute, as part of a collaboration between Georgetown University and MedStar Health. In this role, he oversees the clinical operations of the MedStar Health cancer service line, and leads the development and coordination of clinical care and research programs spanning prevention, treatment, rehabilitation, survivorship and end-of-life care. With Georgetown Lombardi as the institute’s “research engine,” patients throughout the region served by MedStar Health hospitals will have more opportunities to participate in clinical trials that are at the forefront of screening and treatment advances.
An internationally recognized medical oncologist specializing in the treatment in gastrointestinal cancers, Dr. Weiner is also an accomplished researcher developing novel immunotherapy treatments in his laboratory. He is recognized for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient's immune system to fight cancer using monoclonal antibodies — laboratory-crafted proteins designed to recognize specific cancer cells. His laboratory produces and designs new antibody-based proteins with the aim of improving their tumor-targeting and immune-stimulating properties. This research has led to the surprising and clinically important observation that tumor targeting is impaired if the antibodies attach too tightly to their tumor targets. Dr. Weiner has also developed, and has clinically tested, ”bispecific“ antibodies and related antibody-based proteins designed not only to recognize and bind to cancer cells but also to stimulate immune-system cells to attack the targeted cancer cells.
Dr. Weiner serves as the fourth director of Georgetown Lombardi. Named in honor of all-star football coach Vincent T. Lombardi, the center was founded at Georgetown University in 1971 by John F. Potter, MD, a member of Vince Lombardi’s oncology team. In 1974, in conjunction with Howard University, Lombardi Cancer Center became the 16th National Cancer Institute designated comprehensive cancer center. The designation was renewed for Georgetown Lombardi as a single site in 1990 under Marc Lippman, MD, and again in 2003 under Richard Pestell, MD, PhD.
Dr. Weiner earned his bachelor degree in biology with honors from the University of Pennsylvania and his medical degree from Mount Sinai School of Medicine at New York University. After completing his internship, residency and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston.
Prior to joining Georgetown Lombardi, Dr. Weiner served as chairman of the medical oncology department and vice president for translational research at Fox Chase Cancer Center in Philadelphia. He held an endowed chair in medical science and was the driving force behind the development of clinical programs and an immunotherapy laboratory, as well as the establishment of the center’s medical oncology fellowship program. Dr. Weiner also served as professor in the department of medicine at Temple University School of Medicine
Board certified in internal medicine and medical oncology by the American Board of Internal Medicine, Dr. Weiner has published more than 200 scientific papers. He also lectures extensively on targeted therapies for cancer. From 1994 through 2002, he served as Fox Chase Cancer Center’s principal investigator for the Eastern Cooperative Oncology Group (ECOG), a major national study group working to improve cancer treatment through clinical trials. Dr. Weiner is also chair of the Immunology Task Force of the American Association for Cancer Research as well as course director for the annual AACR/ASCO Clinical Methods Workshop. He serves as chair of the NCI’s Board of Scientific Counselors – Clinical Sciences and Epidemiology and as a member of its Clinical Trials and Translational Research Advisory Committee. He serves on the steering committee of the NCI Translational Research Working Group and on the NCI’s RAID Oversight Committee. He is a standing member of the Cancer Immunopathology and Immunotherapy Study Section of the National Institutes of Health.
Active in many professional organizations, Dr. Weiner is on several journal editorial boards, including Cancer Research and Clinical Cancer Research, and also reviews manuscripts for numerous peer-reviewed medical journals. He has received research awards from the American Cancer Society-Southeast Region, Janssen Pharmaceutical Research Foundation and the Israel Cancer Research Fund. He also has received career development awards from the American Cancer Society and National Cancer Institute.